Buck E. Rogers, Ph.D.
Professor of Radiation Oncology
Professor of Radiology


The major focus of research in the Rogers lab is the radiolabeling of proteins and peptides with various radioactive metals (Cu-64, Ga-68, Zr-89, Y-86,90) for imaging and therapy of cancer.  The main targets have been the somatostatin receptor subtype 2 (SSTR2) and the gastrin-releasing peptide receptor (GRPR) that are overexpressed on neuroendocrine, prostate, and breast cancers.  Analogs of the eight amino acid peptide, octreotide, are generally used for targeting SSTR2, while analogs of the fourteen amino acid bombesin peptide are generally used for targeting GRPR.  These peptides are conjugated with bifunctional chelators for complexing various radioactive metals.  Another major area of interest is the development of an imaging system that can be used for non-invasive monitoring gene transfer in gene therapy protocols in collaboration with Dr. Curiel.  For the non-invasive monitoring of gene therapy we would like to determine the location, magnitude and change in magnitude over time of the expression of delivered genes.  For this, we have used adenoviral vectors encoding SSTR2 that can be targeted with radiolabeled octreotide analogs.  Finally, we are developing imaging agents based on an scFv phage display library developed in our lab.  These studies also involve collaborations in the Department of Radiology for small animal imaging using microPET and microCT.

Buck Rogers, Ph.D.


Dr. Rogers is a Professor of Radiation Oncology and Associate Professor of Radiology.  His graduate work involved the synthesis of bifunctional chelating agents for studying the metabolism of radiolabeled antibodies under the direction of Dr. Michael J. Welch.   Dr. Rogers went on to complete a postdoctoral research fellowship under the direction of Dr. Donald J. Buchsbaum at the University of Alabama at Birmingham (UAB).  In 2002, he returned to Washington University as an Assistant Professor and was promoted to Associate Professor (tenured) in 2007.  Dr. Rogers has co-authored more than 50 peer-reviewed papers in national and international journals as well as numerous abstracts, book chapters, and patents.  He is also an Editor for Nuclear Medicine and Biology and Current Medical Imaging Reviews.  He is a member of several societies and has served on Study Sections for the NIH, Department of Energy, and American Cancer Society.


4511 Forest Park Blvd., Suite 411

Campus Box



St. Louis, MO 63108


Forest Park  A5


(314) 362-9787


(314) 362-9790




  • PhD, Inorganic Chemistry, Washington University, 1995
  • AM, Washington University, 1991
  • BS, Loyola University of Chicago, 1989


  • Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T:  MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-Demotate 1.  J Nucl Med 46:1889-1897, 2005.
  • Parry JJ, Andrews R, Rogers BE:  MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.  Breast Cancer Res Treat 101:175-183, 2007.
  • Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, Rogers BE:  Characterization of somatostatin receptor subtype  2 expression in stably transfected A-427 human cancer cells.  Mol Imaging 6:56-67, 2007.
  • Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS:  Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1-14).  Bioconjug Chem 18:724-730, 2007.
  • Parry JJ, Kelly TS, Andrews R, Rogers BE:  In vitro and in vivo evaluation of 64Cu-labeled DOTA-Linker-Bombesin(7-14) analogs containing different amino acid linker moieties.  Bioconjug Chem 18:1110-1117, 2007.
  • Eiblmaier M, Andrews R, Laforest R, Rogers BE, Anderson CJ: Nuclear uptake and dosimetry of 64Cu-labeled chelator-somatostatin conjugates in a SSTr2-transfected human tumor cell line. J Nucl Med 48:1390-1396, 2007.
  • Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, Anderson CJ, Achilefu S: The agonist-antagonist dilemma in molecular imaging: Evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.  Bioconjug Chem 19:192-200, 2008.
  • Parry JJ, Sharma V, Andrews R, Moros EG, Piwnica-Worms D, Rogers BE: PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts.  Cancer Gene Ther 16:161-170, 2009.
  • Geng L, Rachakonda G, Morré DJ, Morré DM, Crooks PA, Sonar VN, Roti Roti JL, Rogers BE, Greco S, Ye F, Salleng KJ, Sasi S, Freeman ML, Sekhar KR: Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.  FASEB J 23:2986-2995, 2009.
  • Kitamura T, Fukuyo Y, Inoue M, Horikoshi NT, Shindoh M, Rogers BE, Usheva A, Horikoshi N: Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-dependent stabilization of Daxx.  Cancer Res 69:7681-7688, 2009.
  • Chen R, Parry JJ, Akers WJ, Berezin MY, El Naqa IM, Achilefu S, Edwards WB, Rogers BE: Multimodality Imaging of Gene Transfer Using a Receptor-Based Reporter Gene.  J Nucl Med 51:1456-1463, 2010.
  • Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE:  In vitro and in vivo evaluation of 64Cu-Labeled SarAr-Bombesin Analogs in Gastrin-Releasing Peptide Receptor-Expressing Prostate Cancer.  J Nucl Med 52:470-477, 2011.
Print this page | Close
spacer spacer spacer